HIV & Hepatitis Coinfection HIV/HBV Coinfection
HIV/HBV Coinfection
Complete Coverage of the 2012 International Liver Congress
- Details
- Category: HBV Treatment
- Published on Wednesday, 25 April 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 2012 International Liver Congress -- 47th Annual Meeting of the European Association for the Study of the Liver (EASL), April 18-22.
Conference highlights include experimental hepatitis C therapies, interferon-free regimens, boceprevir (Victrelis) and telaprevir (Incivek/Incivo) in real-world practice, difficult-to-treat patients, HIV/HCV coinfection, hepatitis B research, and liver cancer research.
HIVandHepatitis.com EASL 2012 conference section
CROI: Detectable HIV Raises Risk of Incomplete Hepatitis B Suppression
- Details
- Category: HIV/HBV Coinfection
- Published on Tuesday, 27 March 2012 00:00
- Written by Liz Highleyman
HIV/HBV coinfected people with detectable HIV viral load and higher baseline HBV viral load were less likely to completely suppress hepatitis B after a year on tenofovir (Viread), but CD4 cell count did not show an effect, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this month in Seattle.
Hepatitis Delta Found in 15% of HIV/HBV Coinfected People, Increases Risk of Death
- Details
- Category: Hepatitis Delta (HDV)
- Published on Thursday, 01 September 2011 00:00
- Written by Liz Highleyman
Approximately 15% of people with HIV who test positive for hepatitis B surface antigen (HBsAg) also carry hepatitis delta virus (HDV), a defective virus that can only replicate in the presence of hepatitis B virus (HBV) but can lead to more severe liver damage, according to a recent European study.
CROI: Long-term Tenofovir Promotes HBsAg Decline in HIV/HBV Coinfected People
- Details
- Category: HIV/HBV Coinfection
- Published on Tuesday, 20 March 2012 00:00
- Written by Liz Highleyman
Hepatitis B surface antigen (HBsAg) levels declined steadily in HIV/HBV coinfected patients treated with tenofovir for up to 8 years, especially those with rising CD4 T-cell counts, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this month in Seattle.
Treating HIV/HBV Coinfection in Africa
- Details
- Category: HIV/HBV Coinfection
- Published on Friday, 08 July 2011 13:16
- Written by Liz Highleyman
Antiretroviral therapy regimens containing lamivudine did not provide notable benefit or reduce mortality among HIV/HBV coinfected patients in South African, suggesting that tenofovir (Viread) may be a better option.
HIV/HBV Coinfection Raises Risk of AIDS Progression and Death
- Details
- Category: HIV/HBV Coinfection
- Published on Tuesday, 13 December 2011 00:00
- Written by Liz Highleyman
Coinfection with hepatitis B virus (HBV) nearly doubled the risk of progression to AIDS or death among people recently infected with HIV, according to a study described in the December 5, 2011, advance online edition of the Journal of Infectious Diseases.
Additional HBV Vaccine Dose Offers More Protection for People with HIV
- Details
- Category: HBV Vaccines
- Published on Saturday, 23 April 2011 09:18
- Written by Paul Dalton
Two alternative dosing schedules of hepatitis B virus (HBV) vaccination led to higher levels of protection than the standard 3-dose schedule. 
CDC Offers New HIV and Hepatitis Coinfection Fact Sheet
- Details
- Category: HIV/HBV Coinfection
- Published on Tuesday, 29 November 2011 00:00
- Written by Liz Highleyman
The U.S. Centers for Disease Control and Prevention (CDC) have produced a new fact sheet providing information about viral hepatitis in people with HIV.
EASL: Kidney Function in HIV/HBV Coinfected People on Tenofovir
- Details
- Category: HIV/HBV Coinfection
- Published on Tuesday, 19 April 2011 09:34
- Written by Liz Highleyman
Impaired kidney function among people with HIV, HBV, and HIV/HBV coinfection taking tenofovir mainly occurred in those with pre-existing risk factors, researchers reported at EASL 2011. 
AASLD: Long-term Tenofovir for HIV/HBV Coinfection
- Details
- Category: HBV Treatment
- Published on Tuesday, 08 November 2011 00:00
- Written by Liz Highleyman
Tenofovir showed long-term antiviral activity against hepatitis B virus (HBV) lasting 5 to 8 years, with minimal evidence of kidney toxicity, and HBsAg levels declined steadily over time, according to 2 posters presented this week at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.
Tenofovir Remains Effective against Hepatitis B Virus after 5 Years in HIV/HBV Coinfected Patients
- Details
- Category: HIV/HBV Treatment
- Published on Friday, 25 February 2011 03:53
- Written by Liz Highleyman
Tenofovir (Viread, also in the Truvada and Atripla combination pills) continues to potently suppress both hepatitis B virus (HBV) and HIV in coinfected patients for at least 5 years, according to a study published in the December 2010 issue of Gastroenterology. The findings support current guidelines recommending that HIV/HBV coinfected people should receive an antiretroviral therapy (ART) regimen that includes drugs with dual action against both viruses.
Hepatitis B and C Coinfection among HIV Positive People in the U.S.
- Details
- Category: HIV/HBV Coinfection
- Published on Monday, 12 September 2011 00:00
- Written by Liz Highleyman
Liver disease and coinfection with hepatitis B or C are common among people with HIV, according to a recent analysis, leading researchers to recommend that viral hepatitis screening, vaccination, and treatment should be considered a priority for HIV positive individuals.
Coinfected People May Control HIV but not HBV on a Tenofovir Regimen
- Details
- Category: HIV/HBV Coinfection
- Published on Friday, 10 December 2010 12:48
- Written by Liz Highleyman
More then one-third of people coinfected with HIV and hepatitis B virus (HBV) did not achieve or maintain HBV suppression after 1 year of taking tenofovir (Viread), even though they had undetectable HIV viral load indicating good adherence, according to study findings presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) in Boston.
